Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Debt to Equity: 2009-2016

Historic Debt to Equity for Gyre Therapeutics (GYRE) over the last 7 years, with Sep 2016 value amounting to $0.00.

  • Gyre Therapeutics' Debt to Equity fell 92.35% to $0.00 in Q3 2016 from the same period last year, while for Sep 2016 it was $0.00, marking a year-over-year decrease of 92.35%. This contributed to the annual value of $0.04 for FY2015, which is N/A change from last year.
  • Per Gyre Therapeutics' latest filing, its Debt to Equity stood at $0.00 for Q3 2016, which was down 74.20% from $0.01 recorded in Q2 2016.
  • Gyre Therapeutics' 5-year Debt to Equity high stood at $0.04 for Q4 2015, and its period low was -$0.02 during Q4 2012.
  • Over the past 3 years, Gyre Therapeutics' median Debt to Equity value was $0.01 (recorded in 2014), while the average stood at $0.01.
  • As far as peak fluctuations go, Gyre Therapeutics' Debt to Equity tumbled by 214.97% in 2012, and later surged by 341.03% in 2015.
  • Gyre Therapeutics' Debt to Equity (Quarterly) stood at -$0.02 in 2012, then soared by 48.19% to -$0.01 in 2013, then slumped by 54.02% to $0.00 in 2014, then skyrocketed by 341.03% to $0.04 in 2015, then tumbled by 92.35% to $0.00 in 2016.
  • Its last three reported values are $0.00 in Q3 2016, $0.01 for Q2 2016, and $0.01 during Q1 2016.